12/4
04:39 pm
zbio
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]
Medium
Report
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]
11/26
08:19 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.
11/20
09:14 am
zbio
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
Medium
Report
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
11/13
08:28 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.
11/12
09:57 am
zbio
Zenas BioPharma, Inc. GAAP EPS of -$1.22 [Seeking Alpha]
Low
Report
Zenas BioPharma, Inc. GAAP EPS of -$1.22 [Seeking Alpha]
11/12
07:05 am
zbio
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/11
07:05 am
zbio
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Medium
Report
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
11/8
01:18 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at
Wall Street Ze
10/30
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
10/30
12:32 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/28
10:59 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/28
08:09 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at HC Wainwright from $30.00 to $44.00. They now have a "buy" rating on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at HC Wainwright from $30.00 to $44.00. They now have a "buy" rating on the stock.
10/27
11:08 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $40.00.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $40.00.
10/27
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
10/27
03:59 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
10/27
07:05 am
zbio
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
High
Report
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
10/9
09:25 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Wedbush from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Wedbush from $35.00 to $40.00. They now have an "outperform" rating on the stock.
10/9
08:07 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/9
08:01 am
zbio
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal [Seeking Alpha]
Low
Report
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal [Seeking Alpha]
10/8
05:34 pm
zbio
Zenas BioPharma files automatic mixed securities shelf [Seeking Alpha]
Medium
Report
Zenas BioPharma files automatic mixed securities shelf [Seeking Alpha]
10/8
12:39 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
05:11 am
zbio
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis [Yahoo! Finance]
Medium
Report
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis [Yahoo! Finance]
10/8
05:00 am
zbio
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
High
Report
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
10/3
03:48 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/27
12:39 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at
Wall Street
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at
Wall Street